Jubilant Pharmova Limited (JUBLPHARMA) - Total Liabilities
Based on the latest financial reports, Jubilant Pharmova Limited (JUBLPHARMA) has total liabilities worth Rs69.50 Billion INR (≈ $751.56 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Jubilant Pharmova Limited liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Jubilant Pharmova Limited - Total Liabilities Trend (2004–2025)
This chart illustrates how Jubilant Pharmova Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Jubilant Pharmova Limited (JUBLPHARMA) total assets.
Jubilant Pharmova Limited Competitors by Total Liabilities
The table below lists competitors of Jubilant Pharmova Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Jahwa United Co Ltd
SHG:600315
|
China | CN¥3.55 Billion |
|
SRH Total Return Fund Inc.
NYSE:STEW
|
USA | $230.72 Million |
|
Dunelm Group plc
F:DFQ
|
Germany | €608.30 Million |
|
Douglas Emmett Inc
NYSE:DEI
|
USA | $5.87 Billion |
|
Jeudan
CO:JDAN
|
Denmark | Dkr25.28 Billion |
|
Indo Tambangraya Megah Tbk
JK:ITMG
|
Indonesia | Rp475.20 Million |
|
Xiamen ITG Group Corp Ltd
SHG:600755
|
China | CN¥102.92 Billion |
|
Telecom Argentina S.A
F:TEO
|
Germany | €10.33 Trillion |
Liability Composition Analysis (2004–2025)
This chart breaks down Jubilant Pharmova Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Jubilant Pharmova Limited to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jubilant Pharmova Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jubilant Pharmova Limited (2004–2025)
The table below shows the annual total liabilities of Jubilant Pharmova Limited from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs65.18 Billion ≈ $704.88 Million |
+6.37% |
| 2024-03-31 | Rs61.27 Billion ≈ $662.66 Million |
+6.29% |
| 2023-03-31 | Rs57.65 Billion ≈ $623.45 Million |
+23.33% |
| 2022-03-31 | Rs46.74 Billion ≈ $505.53 Million |
+11.92% |
| 2021-03-31 | Rs41.77 Billion ≈ $451.68 Million |
-39.63% |
| 2020-03-31 | Rs69.18 Billion ≈ $748.13 Million |
+3.88% |
| 2019-03-31 | Rs66.59 Billion ≈ $720.20 Million |
+19.29% |
| 2018-03-31 | Rs55.83 Billion ≈ $603.74 Million |
-1.09% |
| 2017-03-31 | Rs56.44 Billion ≈ $610.37 Million |
-6.52% |
| 2016-03-31 | Rs60.37 Billion ≈ $652.93 Million |
-2.29% |
| 2015-03-31 | Rs61.79 Billion ≈ $668.20 Million |
+1.69% |
| 2014-03-31 | Rs60.76 Billion ≈ $657.11 Million |
+4.29% |
| 2013-03-31 | Rs58.26 Billion ≈ $630.07 Million |
+6.96% |
| 2012-03-31 | Rs54.47 Billion ≈ $589.09 Million |
+1.82% |
| 2011-03-31 | Rs53.50 Billion ≈ $578.56 Million |
+16.67% |
| 2010-03-31 | Rs45.85 Billion ≈ $495.88 Million |
-14.07% |
| 2009-03-31 | Rs53.36 Billion ≈ $577.07 Million |
+80.69% |
| 2008-03-31 | Rs29.53 Billion ≈ $319.38 Million |
+26.36% |
| 2007-03-31 | Rs23.37 Billion ≈ $252.75 Million |
+93.04% |
| 2006-03-31 | Rs12.11 Billion ≈ $130.93 Million |
+59.66% |
| 2005-03-31 | Rs7.58 Billion ≈ $82.00 Million |
+14.92% |
| 2004-03-31 | Rs6.60 Billion ≈ $71.36 Million |
-- |
About Jubilant Pharmova Limited
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment o… Read more